TOP TEN perturbations for 38508_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38508_s_at
Selected probe(set): 213451_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38508_s_at (213451_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):-6.256318Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):-5.92817Number of Samples:6 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):-5.7716627Number of Samples:3 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):-5.504034Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):-5.4267426Number of Samples:7 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, sarcoma, NOS of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Relative Expression (log2-ratio):5.398384Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):5.177845Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-4.90283Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):4.7944393Number of Samples:2 / 4
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary clear cell adenocarcinoma (NOS) of the ovary. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-4.6781397Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
Organism: Homo sapiens
Gene: 38508_s_at
Selected probe(set): 217413_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38508_s_at (217413_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.8735132Number of Samples:3 / 3
| Experimental | influenza virus study 9 (A/H9N2) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.7977991Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):1.6187935Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):-1.4994507Number of Samples:2 / 4
| Experimental | glioma study 17 ( small cell glioblastoma; unsorted) |
| Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.4480762Number of Samples:3 / 3
| Experimental | influenza virus study 9 (A/H5N2) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):1.4414873Number of Samples:3 / 5
| Experimental | ovarian tumor study 16 |
| Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.4372501Number of Samples:3 / 3
| Experimental | influenza virus study 10 (A/H5N2) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):1.420268Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
| Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.4127941Number of Samples:3 / 3
| Experimental | influenza virus study 9 (A/pH1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
ALDH1A1/ALDH3A1 depletion study 1 (siRNA) / control transfected A-549 cell sample
Relative Expression (log2-ratio):1.3694057Number of Samples:4 / 4
| Experimental | ALDH1A1/ALDH3A1 depletion study 1 (siRNA) |
| Human primary cancer cell line A-549 stably transduced with lentiviral vectors containing specific siRNA sequences against ALDH1A1 (Aldehyde dehydrogenase 1 family, member A1) and ALDH3A1 (Aldehyde dehydrogenase 3 family, member A1) (Lenti 1+3 cells). | |
| Control | control transfected A-549 cell sample |
| Human primary cancer cell line A-549 stably transduced with lentiviral vector containing siRNA against GFP. 4 clones of control cell line were prepared (clone GFP1-4). |